mots-c

mots-c (also known as MOTS-c or Mitochondrial ORF of the 12S rRNA type-c) is a performance-enhancing peptide studied for its effects on metabolic health, fat loss, anti-aging. Mitochondrial peptide activating AMPK to boost insulin sensitivity and mimic exercise adaptations. Investigational, WADA-prohibited, preclinical evidence only.

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial genome rather than the nuclear DNA. It functions as a regulator of metabolic homeostasis: under metabolic stress such as glucose restriction or exercise, MOTS-c translocates from the cytoplasm to the nucleus, where it helps direct an adaptive antioxidant and metabolic stress response, in part through activation of AMP-activated protein kinase (AMPK). In cell and rodent models it enhances glucose uptake and insulin sensitivity, improves lipid metabolism, reduces diet-induced obesity, and reproduces and amplifies several of the metabolic adaptations normally produced by physical exercise, leading some researchers to describe it as an 'exercise-mimetic' peptide.

Overview

Circulating MOTS-c levels decline with age and are altered in metabolic disease.

MOTS-c is an investigational research peptide with no approved human indication, and it is banned by the World Anti-Doping Agency (WADA) as a prohibited metabolic modulator, explicitly named as an AMP-activated protein kinase (AMPK) activator under category S4.4.1 and banned at all times, in and out of competition, since the 2025 Prohibited List.

Human data are largely limited to observational associations between endogenous MOTS-c levels and fitness or metabolic status; demonstrated efficacy comes from preclinical cell and animal experiments, not controlled human trials.

Mechanism of action

Mitochondrial-derived peptide that activates AMPK to improve insulin sensitivity and reproduce exercise-like metabolic adaptations in preclinical models. Investigational and WADA-banned; no approved human use.

Reported effects

Effects reported in the literature and from preclinical models include:

• MOTS-c enhanced insulin sensitivity in the skeletal muscle of gestational diabetic mice and elevated glucose uptake in vitro. ^[2] Preclinical
• In a gestational diabetes mouse model, MOTS-c alleviated hyperglycemia, improved glucose tolerance, protected pancreatic beta-cells from streptozotocin injury, and reduced offspring death. ^[2] Preclinical
• Systemic MOTS-c administration increased exercise performance by boosting skeletal muscle stress responses and enhancing metabolic adaptation to exercise. ^[3] Preclinical
• Exogenous MOTS-c stimulated thermogenesis in subcutaneous white adipose tissue, which increased energy expenditure and contributed to the anti-obesity effects of exercise training. ^[3] Preclinical
• Under glucose restriction, MOTS-c translocated to the nucleus and regulated antioxidant response element genes in an AMPK-dependent manner, interacting with the stress-responsive transcription factor NRF2. ^[1] Preclinical
• Exogenous MOTS-c attenuated lung injury in preclinical models, while circulating levels are reduced in acute respiratory distress and in chronic respiratory disease. ^[4] Preclinical

Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal

Dosage and administration

General

• Investigational research peptide with no established or approved human dose
• Rodent studies use intraperitoneal dosing in the 0.5-15 mg/kg range
• Human interventional dosing has not been validated in controlled trials

Natty status

mots-c is classified as not natty. It appears on the WADA prohibited list and is banned by major natural bodybuilding federations.^[5] Use of this compound places the athlete in the enhanced category rather than the natural category in competitive contexts.

Research

The peptide has been the subject of 6 studies and reference works collected on this site. Additional bibliography is in § External links below.

Related compounds

Other peptides in this catalogue with overlapping mechanisms or status:

References

1. ^ The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Metabolic Homeostasis (Cell Metab 2018)
2. ^ a b MOTS-c relieves hyperglycemia and insulin resistance (preclinical, Pharmacol Res 2022)
3. ^ a b Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c) (review, Diabetes Metab J 2022) Recent
4. ^ MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases. Recent review
5. ^ a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
• Wikipedia article
• 10mg MOTS-c — commercial